RAPT Therapeutics Inc (RAPT)
2.72
-0.07
(-2.51%)
USD |
NASDAQ |
Jul 03, 16:00
RAPT Therapeutics Research and Development Expense (TTM): 100.21M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 100.21M |
| December 31, 2023 | 101.00M |
| September 30, 2023 | 93.69M |
| June 30, 2023 | 83.27M |
| March 31, 2023 | 75.99M |
| December 31, 2022 | 67.08M |
| September 30, 2022 | 61.93M |
| June 30, 2022 | 61.05M |
| March 31, 2022 | 59.88M |
| December 31, 2021 | 56.98M |
| September 30, 2021 | 53.59M |
| Date | Value |
|---|---|
| June 30, 2021 | 50.78M |
| March 31, 2021 | 48.57M |
| December 31, 2020 | 45.48M |
| September 30, 2020 | 44.77M |
| June 30, 2020 | 40.44M |
| March 31, 2020 | 37.72M |
| December 31, 2019 | 34.91M |
| September 30, 2019 | 33.10M |
| June 30, 2019 | 33.70M |
| March 31, 2019 | 32.33M |
| December 31, 2018 | 31.77M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
33.10M
Minimum
Sep 2019
101.00M
Maximum
Dec 2023
60.55M
Average
56.98M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Ironwood Pharmaceuticals Inc | 129.05M |
| Tonix Pharmaceuticals Holding Corp | 73.01M |
| Skye Bioscience Inc | 6.581M |
| Allakos Inc | 152.65M |
| X4 Pharmaceuticals Inc | 69.81M |